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Abstract
Introduction The etiology of familial breast cancer is complex
and involves genetic and environmental factors such as
hormonal and lifestyle factors. Understanding familial
aggregation is a key to understanding the causes of breast
cancer and to facilitating the development of effective
prevention and therapy. To address urgent research questions
and to expedite the translation of research results to the clinical
setting, the National Cancer Institute (USA) supported in 1995
the establishment of a novel research infrastructure, the Breast
Cancer Family Registry, a collaboration of six academic and
research institutions and their medical affiliates in the USA,
Canada, and Australia.
Methods The sites have developed core family history and
epidemiology questionnaires, data dictionaries, and common
protocols for biospecimen collection and processing and
pathology review. An Informatics Center has been established
to collate, manage, and distribute core data.
Results As of September 2003, 9116 population-based and
2834 clinic-based families have been enrolled, including 2346
families from minority populations. Epidemiology questionnaire
data are available for 6779 affected probands (with a personal
history of breast cancer), 4116 unaffected probands, and
16,526 relatives with or without a personal history of breast or
ovarian cancer. The biospecimen repository contains blood or
mouthwash samples for 6316 affected probands, 2966
unaffected probands, and 10,763 relatives, and tumor tissue
samples for 4293 individuals.
Conclusion This resource is available to internal and external
researchers for collaborative, interdisciplinary, and translational
studies of the genetic epidemiology of breast cancer. Detailed
information can be found at the URL http://www.cfr.epi.uci.edu/.
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Introduction
Breast cancer is known to be 'familial', both from the clinical
perspective of observing more families with multiple cases
than would be expected by chance, and from the popula-
tion perspective of an increased risk of breast cancer
among women with a family history of the disease. The two-
fold to threefold increased risk to first-degree relatives of
affected women is likely to be due to underlying familial fac-
tors, both genetic and environmental (for example, hormo-
nal and lifestyle factors), and the risk gradient across these
factors must be 20–100-fold or more [1,2]. Understanding
the interplay of genetic and environmental causes of familial
aggregation is therefore a key to understanding the causes
of breast cancer and to facilitating the development of
effective prevention and therapy.
Much is yet to be learned about the causes of familial
aggregation of breast cancer. Pathogenic mutations in the
genes BRCA1 [3] and BRCA2 [4] are associated with
large individual increased risks, on the order of 10–20-fold,
but, being rare, they explain less than 20% of the increased
risk associated with having an affected first-degree relative
[1,5]. Less than half the families with three or more affected
members in the Breast Cancer Linkage Consortium have
segregating deleterious mutations in BRCA1 or BRCA2
[6]. Mutations in TP53 [7], and possibly in the ATM [8] and
CHK2  [9] genes, seem to confer moderately increased
risks of breast cancer but might explain only a very small
proportion of familial aggregation. Breast cancer risk might
also be affected by multiple variants in genes involved with
hormonal or other etiological pathways, and the variants
might be common and have small or modest effects on indi-
vidual risk. Lifestyle and other known risk factors are
unlikely to explain much familial aggregation [2]. The effects
of some established lifestyle factors might vary in relation to
family history [10] or BRCA1 or BRCA2 mutation status
[11]. Thus, familial aspects of breast cancer are complex,
potentially involving multiple genes, multiple environmental
exposures, and 'gene–environment interactions' [12].
To address many unanswered research questions regard-
ing the etiology of breast cancer and to expedite the trans-
lation of research results to affected and at-risk
populations, the National Cancer Institute of the USA sup-
ported the establishment of a novel international research
infrastructure for interdisciplinary and translational studies
of the genetic epidemiology of breast cancer. The Breast
Cancer Family Registry is a collaboration of six academic
and research institutions and their medical affiliates located
in the USA, Canada, and Australia. This paper describes
the development of the Breast Cancer Family Registry
research infrastructure, the resources available to the
research community as of September 2003, and many of
the possible studies using this resource.
Methods
Structure of the Breast Cancer Family Registry
The Breast Cancer Family Registry was established in
1995, with six participating sites from the USA, Canada,
and Australia ascertaining families either from cancer regis-
tries (identifying population-based families) or seen in clini-
cal and community settings (identifying clinic-based
families) (Fig. 1). Population-based families were recruited
from the Greater San Francisco Bay area, California, USA,
by the Northern California Cancer Center; from the prov-
ince of Ontario, Canada, by Cancer Care Ontario; and from
the metropolitan areas of Melbourne and Sydney, Australia,
by the University of Melbourne and the New South Wales
Cancer Council. Clinic-based families, including those of
Ashkenazi Jewish ancestry, were recruited from their local
populations in the USA by Columbia University in New York
City, New York, the Fox Chase Cancer Center in Philadel-
phia, Pennsylvania, and Huntsman Cancer Institute at the
University of Utah in Salt Lake City, Utah; and in Australia
by the University of Melbourne and New South Wales Can-
cer Council in Melbourne and Sydney, Australia. In Ontario,
Canada, recruitment of clinic-based families was limited to
Ashkenazi Jewish families.
The Breast Cancer Family Registry investigators include
epidemiologists, molecular biologists, molecular geneti-
cists, clinicians, geneticists, genetic counselors, statisti-
cians, pathologists and behavioral scientists. The
participating sites are supported through Cooperative
Agreements; thus, the leadership and scientific conduct of
the Breast Cancer Family Registry are a combined effort of
the six principal investigators and their teams, with substan-
tial involvement of the Program Officer and other represent-
atives of the National Cancer Institute.
Policy and governance
The six sites have collaborated to develop and maintain the
resources, to conduct interdisciplinary research, and to
establish collaborations with external investigators. An
organizational chart for the Breast Cancer Family Registry
is provided in Fig. 2. Detailed information on the govern-
ance and policy can be found at the URL http://
www.cfr.epi.uci.edu/nci/access_manual_05-29-02.htm.
Research proposals from both internal and external investi-
gators requesting access to the Breast Cancer Family Reg-
istry resources are evaluated by an Advisory Committee for
scientific merit and the appropriate use of resources on the
basis of criteria established by the Steering Committee of
the Breast Cancer Family Registry. The decisions of the
Advisory Committee are then reviewed and ratified by the
Steering Committee.
Informatics Center
In 1998 an Informatics Center was established at the Uni-
versity of California, Irvine. The Informatics Center hasAvailable online http://breast-cancer-research.com/content/6/4/R375
R377
developed a flexible and evolving informatics model, which
maintains an Oracle relational database using a 'minimal
data set' to track subjects. The Informatics Center receives
standard data on several modules including family history,
epidemiologic risk factors, diet, biospecimen tracking, gen-
otyping, pathology, and follow-up data. The Informatics
Center collates, manages, and distributes core data, in col-
laboration with each of the six local informatics units. Data
from each site are submitted in batches to the Central Infor-
matics System with the use of a secure access procedure.
A quality assurance system ensures the reliability, validity,
and completeness of the database. Up-to-date extract files
are created from the relational database and are distributed
to investigators. The Informatics Center also maintains the
website for the Breast Cancer Family Registry http://
www.cfr.epi.uci.edu, and coordinates teleconferences and
other activities between the sites, the Advisory Committee,
the Steering Committee, the National Cancer Institute, and
the Informatics Center.
Ascertainment of probands and family members
Most families were enrolled in the Breast Cancer Family
Registry from 1996 to 2000. During the period 2001–
2005, several sites are continuing to recruit the following:
(1) families known to segregate BRCA1 or BRCA2 muta-
tions; (2) families with multiple cases of breast or ovarian
cancer; (3) selected additional relatives of previously
enrolled families; (4) families of Ashkenazi Jewish ancestry;
and (5) families from specific racial and ethnic groups.
Clinic-based and community-based recruitment
Four sites enrolled families with multiple or early-onset
cases of breast or ovarian cancer identified through com-
munity contacts and clinical settings including screening
Figure 1
Structure of the Breast Cancer Family Registry Structure of the Breast Cancer Family Registry.
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centers, family cancer clinics, surgical and medical oncol-
ogy offices, and the Australian twin registry. Probands were
defined as the first family member enrolled in the Breast
Cancer Family Registry and may or may not have had a per-
sonal history of breast or ovarian cancer. Eligibility was
based on one or more of the following criteria: two or more
relatives with a personal history of breast or ovarian cancer;
a woman diagnosed with breast or ovarian cancer at a
young age; a woman with a history of both breast and ovar-
ian cancer; an affected male; or known BRCA1 or BRCA2
mutation carriers. The Australian site also enrolled twin
pairs in which one or both members had a personal history
of breast cancer. Table 1 shows the eligibility criteria and
family characteristics of clinic-based probands for each
site.
Population-based recruitment
Three sites enrolled families through females with incident
breast cancer identified through population-based cancer
registries in defined geographic areas. Two sites also
enrolled families through male breast cancer cases. Case
probands, defined as the affected persons ascertained
from a cancer registry, were sampled according to one or
more criteria, including age at diagnosis, gender, race/eth-
nicity, and family history. Table 2 provides an overview of
the sampling strategies for the population-based case
probands. Control probands were randomly sampled from
the general population living in the relevant catchment area
of each of the regional cancer registries, using random-digit
dialing (San Francisco), lists of randomly selected residen-
tial telephone numbers (Ontario), and electoral rolls (Mel-
bourne and Sydney). At all six sites, permission and
assistance were sought from the proband to contact eligi-
ble relatives.
Special recruitment initiatives
Ashkenazi families
After the discovery that three specific mutations in BRCA1
and  BRCA2  are relatively common among people of
Ashkenazi Jewish ancestry [13], four sites (New York, Phil-
adelphia, Ontario, and Melbourne and Sydney) were
funded between 1996 and 2000 to recruit Ashkenazi Jew-
ish families through their local communities and cancer
family clinics, in addition to those being recruited through
Figure 2
Organization of the Breast Cancer Family Registry Organization of the Breast Cancer Family Registry.
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Table 1
Ascertainment criteria for clinic-based families, including Ashkenazi Jewish, identified at five sites from 1996 to 2000
Parameter Philadelphiaa New Yorka Utahb Melbourne and 
Sydney, Australia
Ontario, Canadac
Geographic area Philadelphia New York, New 
Jersey, Connecticut
Salt Lake City Melbourne, Sydney Province of Ontario
Recruitment criteria 
for families
Male with breast 
cancer; female with 
breast or ovarian 
cancer diagnosed at 
age <35; female 
with breast and 
ovarian cancer 
diagnosed at any 
age; female with 
bilateral breast 
cancer and first 
diagnosis at age 
<50; two individuals 
in two generations 
with breast or 
ovarian cancer; 
BRCA1 or BRCA2 
mutation carrier
Male with breast 
cancer; female with 
breast or ovarian 
cancer diagnosed at 
age <45; female 
with breast and 
ovarian cancer 
diagnosed at any 
age; two first- or 
second-degree or 
three first-, second-, 
or third-degree 
relatives with breast 
or ovarian cancer; 
BRCA1 or BRCA2 
mutation carrier
Male with breast 
cancer; female with 
breast or ovarian 
cancer diagnosed at 
age <45; female 
with breast and 
ovarian cancer 
diagnosed at any 
age; three 
individuals in two 
generations with 
breast or ovarian 
cancer, one 
diagnosed at age 
<45; BRCA1 or 
BRCA2 mutation 
carrier
Two or more first- or 
second-degree 
relatives with breast 
or ovarian cancer 
plus one or more of 
the following: 
additional relative(s) 
with breast or 
ovarian cancer, 
breast cancer 
diagnosed at age 
<40, ovarian cancer 
diagnosed at any 
age, bilateral breast 
cancer, both breast 
and ovarian cancer, 
breast cancer in a 
male relative
Recruitment criteria 
for Ashkenazi 
Jewish families
One Jewish parent Same criteria as 
above
Female with breast or 
ovarian cancer; one 
or more first- or 
second-degree 
relatives with breast 
or ovarian cancer
One Jewish 
grandparent
Relationship to 
proband
First- and second- 
degree relative
First-, second-, and 
third-degree relative
Any relative Any relative
aRecruitment in 2001–2005 is continuing for minority families. bRecruitment in 2001–2005 is continuing for BRCA1 and BRCA2 mutation carrier 
families. cRecruitment in 2001–2005 is continuing for Ashkenazi Jewish families.
Table 2
Ascertainment criteria for probands of population-based families identified at three sites through local cancer registries from 1996 
to 2000
Parameter San Francisco, Californiaa Ontario, Canadab Melbourne and Sydney, Australia
Geographic area Greater San Francisco Bay Area Province of Ontario Metropolitan Areas of Melbourne 
and Sydney
Period of diagnosis 1995–1998 1996–1998 1996–1999
Sampling criteria for females Age 18–34: include all Age 18–35: include all Age 18–39: include all
Age 35–64: include all meeting high 
risk criteriac
Age 36–54: include all meeting high 
risk criteriad or Ashkenazi heritage; 
sample 25% of those not meeting 
high risk criteria
Age 40–49: 50% random sample
Age 35–64: sample 2.5% of whites 
and 15% of minorities not meeting 
high risk criteria
Age 55–69: sample 35% of those 
meeting high risk criteriad or 
Ashkenazi heritage; sample 8.75% 
(35% × 25%) of those not 
meeting high risk criteria
Age 50–59: 25% random sample
Sampling criteria for males Age 20–79: include all Age 20–79: include all Not applicable
aRecruitment in 2001–2005 is continued for minority families from San Francisco Bay area (namely Latino, African-American, Chinese, Japanese, 
and Filipino families) and Orange County, California (namely Latino, African-American, and Filipino families). bRecruitment in 2001–2005 is 
continued for minority families. cBilateral breast cancer with first diagnosis before age 50 years, previous diagnosis of ovarian or childhood cancer, 
one or more first-degree relatives with breast, ovarian or childhood cancer. dPrevious diagnosis of breast or ovarian cancer; at least one first- or 
two second-degree relative(s) with breast or ovarian cancer; at least one second- or third-degree relative with breast cancer diagnosed before age 
36 years, ovarian cancer diagnosed before age 61 years, multiple breast cancer primaries, both breast and ovarian cancer, or male breast cancer; 
at least three first-degree relatives with any combination of breast, ovarian, colon, prostate, or pancreatic cancer or sarcoma, with at least one 
diagnosis before age 51 years.Breast Cancer Research    Vol 6 No 4    John et al.
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the 'core' recruitment activities described above. Individu-
als of Ashkenazi Jewish ancestry were also identified
through the epidemiology or family history questionnaires.
Racial and ethnic minorities
To increase the racial and ethnic diversity of the resource,
special efforts were undertaken at several sites in the USA
to enroll African-American, Asian, and Hispanic families,
either through oversampling of probands (for example, in
San Francisco) or community outreach (for example, in
New York). Recruitment of African-American, Asian, and
Hispanic families is continuing, and in California it has been
expanded to include families from Orange County enrolled
by the University of California, Irvine.
Protocols and procedures
Initially six Working Groups were established to develop
uniform procedures and questionnaires for data and
biospecimen collection and processing: Family History,
Epidemiology, Biospecimens, Pathology, Database, and
Informed Consent. These Working Groups developed the
instruments for data collection, the protocols for biospeci-
men collection, processing, and distribution, and the data
dictionaries to be used at the Informatics Center. An early
challenge was to recognize and respect the geographic dif-
ferences in social, cultural and health care structures and
legislation, while finding common principles, issues, and
language for the questionnaires and informed consent
forms. Core epidemiology and treatment questionnaires
were developed, and common language was incorporated
into each site-specific consent form to address issues
faced by all sites [14].
All sites collected the following: family history data from
probands; epidemiological and dietary data, and blood
samples (or mouthwash samples if venipuncture was
declined) from probands and selected relatives; and clini-
cal and treatment data, tumor blocks and pathology reports
for probands and relatives with a personal history of breast
or ovarian cancer. All data and biospecimens were stored
without personal identifiers.
Questionnaires
Family history questionnaire
Information was sought, at minimum, about previous cancer
diagnoses in the proband and the proband's parents, sib-
lings, and children. Similar information for more distant rel-
atives was also sought depending on site protocols. All
cancers, except non-melanoma skin cancers and cervical
carcinoma in situ, were recorded. Dates of all cancer diag-
noses and deaths were requested.
Epidemiology questionnaire
This instrument obtained information on demographics,
race/ethnicity, religion, personal history of cancer, breast
and ovarian surgeries, radiation exposure, smoking and
alcohol consumption, menstrual and pregnancy history,
breast-feeding, hormone use, weight, height, and physical
activity. Some sites used a short proxy version to collect
limited information on deceased relatives and selected liv-
ing relatives.
Dietary questionnaires
A self-administered food frequency questionnaire devel-
oped by the University of Hawaii [15] for multi-ethnic cohort
studies was used by the five North American sites. The Mel-
bourne and Sydney site used a locally validated dietary
questionnaire developed for a cohort study of Greek, Ital-
ian, and Australian-born inhabitants of Melbourne [16].
Both instruments collected information on frequency of
food consumption and portion size, using photographs to
help in assigning portion sizes.
Treatment questionnaire
Self-reported information was sought on aspects of treat-
ment for breast or ovarian cancer and for any recurrences.
Information from medical records was also collected by
some sites.
Biospecimen collection and processing
A 30 ml sample of blood was requested from probands and
selected relatives, and paraffin blocks or unstained sec-
tions of the paraffin blocks were requested for individuals
with a history of breast or ovarian cancer. From participants
who declined venipuncture, a mouthwash sample was col-
lected at some sites in accordance with the protocol of
Lum and Le Marchand [17]. The New York site also col-
lected urine samples from selected participants for estro-
gen metabolite analyses.
Blood and mouthwash samples
Biospecimen samples were processed at each site, or at a
collaborating laboratory, in accordance with a common
standardized protocol. A quality control program was
developed to allow validation of the methods and their
application at each site. From three tubes of blood, one
tube was used for direct DNA isolation, a second was used
for the preparation of blood spots and plasma, and a third
was collected for the isolation and cryopreservation of lym-
phocytes for future transformation or DNA preparation. To
provide an unlimited source for nucleic acids, Epstein–Barr
virus-transformed lymphoblastoid cell lines from probands
and selected relatives were established [18]. Biospeci-
mens were stored at either the participating academic insti-
tutions or, for some sites, at the Coriell Institute for Medical
Research. Biospecimen collection, processing, annotation,
storage, and distribution for the Breast Cancer Family Reg-
istry were evaluated recently in a report prepared for the
National Cancer Institute and the National Dialogue on
Cancer [19] and it was noted that many of the 'bestAvailable online http://breast-cancer-research.com/content/6/4/R375
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practices' suggested for biospecimen repositories are cur-
rently in use within the Breast Cancer Family Registry.
Pathology specimens
For individuals with a personal history of breast or ovarian
cancer, histological slides and/or paraffin tumor blocks
were requested from the treating institution. Sections were
cut from each block, stained with hematoxylin and eosin,
and reviewed by the site pathologist(s). The pathologists
used standard pathology review forms that were developed
by the Pathology Working Group. A set of 35 invasive car-
cinomas were reviewed by pathologists at all sites, and
agreement was found to be good to excellent for several
pathologic characteristics (Longacre TA, Bane A, Blei-
weiss I, Carter B, Catelano E, Ennis M, Hendrickson MR,
Hibshoosh H, Layfield L, Memeo L, Quenneville L, Venter
DJ, Wu H, O'Malley FP, unpublished data), thus validating
the use of the semi-centralized review process instituted
within the Breast Cancer Family Registry. Representative
blocks of tumors and also of associated benign lesions
were selected by the pathologists for retention in the tissue
repository. All other slides and blocks were returned to the
treating institution. If permission was not obtained to retain
the representative blocks in the repository, sections were
cut in accordance with a standard cutting protocol. This
included cutting 10–20 sections at 4 µm thickness for
future immunohistochemical studies and an additional 10–
20 sections at 10 µm for future DNA extraction. Control
sections, for staining with hematoxylin and eosin, were
taken at the beginning, middle and end of the cutting pro-
tocol as a quality control measure. The specific number of
sections taken from a block depended on the amount of
tumor present in the block. The slides sectioned for future
immunohistochemical studies were placed in either +4°C
fridges or -20 or -80°C freezers. This was to minimize the
risk of any loss of antigenicity, which is known to occur if
unstained sections are stored at room temperature. If per-
mission had been obtained to retain tumor blocks in the
repository, further permission was sought to construct tis-
sue microarrays from these blocks. Tissue microarrays have
been constructed at the Ontario site and are soon to be
constructed at other sites. All pathology reviews were
entered into a database and submitted to the Informatics
Center at the University of California at Irvine.
Validation of breast and ovarian cancer diagnoses
Verification was sought for all reported breast and ovarian
cancers, and at some sites for all reported cancers.
Because the population-based sites ascertained case
probands through cancer registries, verification was neces-
sary only for cancers reported for relatives. The level of con-
fidence regarding a cancer diagnosis was classified into
one of six categories, in decreasing order: (1) review of
slides by Breast Cancer Family Registry pathologist, (2)
pathology report, (3) cancer registry report or medical
records indicating treatment for the specific type of cancer,
(4) report on a death certificate, (5) self-report, and (6)
report by a relative.
Follow-up
Selected participants are being followed to obtain updated
information on cancer and vital status of family members.
For the clinic-based families in the USA, at least one partic-
ipant from each family is contacted annually to update per-
sonal and family cancer histories and deaths, as well as
some exposures addressed in the core epidemiology ques-
tionnaire. In Ontario, an annual mailed follow-up question-
naire to case probands seeks to update births, deaths, and
new cancer diagnoses of case probands and family mem-
bers. The San Francisco site contacts case probands
annually by telephone to update information on cancer and
vital status of the proband and family members. In Australia,
passive record linking to state cancer registries and death
certificates is being conducted, and the medical records of
case probands have been followed up for recurrence and
death [20]. A systematic registry-wide follow-up of all
enrolled probands and relatives is being developed by the
Follow-up Working Group, and is currently being pilot
tested in Australia, Ontario, and San Francisco.
Mutational analysis of BRCA1 and BRCA2
Substantial mutational analyses of BRCA1 and BRCA2
have been undertaken by site laboratories and, more
recently, by Myriad Genetics using full sequence analysis
[21], funded by multiple sources. A validation study was
conducted for five of the methods used between 1997 and
2000, including four DNA-based methods (namely two-
dimensional gene scanning, denaturing high-performance
liquid chromatography, enzymatic mutation detection, and
single-strand conformation polymorphism analysis) and an
RNA/DNA-based method (a protein truncation test) [22].
Single-strand conformation polymorphism analysis was
less sensitive than the other methods and is no longer
being used. The specificity and sensitivity of the other four
methods for protein-truncating mutations were comparable
to those of full sequencing ('gold standard'). Ashkenazi
Jewish participants have been screened for the three
founder mutations, 185delAG and 5382insC in BRCA1
and 6174delT in BRCA2.
Results
Collection of data and biospecimens
As of September 2003, the six sites had enrolled a total of
11,950 families in the Breast Cancer Family Registry
(Table 3). They included 6126 population-based case fam-
ilies and 2990 population-based control families, and 1647
clinic-based families with an affected proband and 1187
clinic-based families with an unaffected proband. Affected
probands included 7111 females with a first primary breast
cancer, 538 females with a second breast cancer, and 124Breast Cancer Research    Vol 6 No 4    John et al.
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males with breast cancer. The enrolled families included
2346 minority families, residing mostly in the USA.
The epidemiology questionnaire was completed by 27,421
participants (10,895 probands and 16,526 relatives), and
the short proxy epidemiology questionnaire was completed
for 20,003 relatives (Table 4). Blood or mouthwash sam-
ples were collected from 20,045 individuals (9282
probands and 10,763 relatives), and tumor tissue was
obtained for 4293 individuals with a history of breast and/
or ovarian cancer (3322 probands and 971 relatives).
Population-based families
Because recruitment of families is continuing in San Fran-
cisco and Ontario, the participation rates below refer to
enrollment from 1996–2000. At each site, before contact
was made with incident breast cancer cases identified from
the regional cancer registry, the case's physician was
contacted. Physician consent was obtained to contact the
great majority of case probands (98% in San Francisco,
92% in Ontario, and 90% in Melbourne and Sydney). In
Ontario and in Melbourne and Sydney, 2% and 3%,
respectively, of the case probands were deceased and
were therefore not studied at those sites. In San Francisco,
family history and epidemiology data for deceased case
probands were collected from proxy respondents.
Eligibility of case probands
To determine eligibility for sampling as a case proband,
information on family history of breast or ovarian cancer
was first obtained through a telephone interview in San
Francisco (84% response rate), and by a mailed question-
naire in Ontario (65% response rate). In Melbourne and
Sydney, all newly diagnosed breast cancer cases were eli-
gible, regardless of family history of breast cancer.
Case probands
Of the eligible case probands, 6126 completed the family
history questionnaire, including 104 males (Table 3), and
5250 completed the epidemiology and treatment question-
naires (76% in San Francisco, 72% in Ontario, and 75% in
Melbourne and Sydney for both the family history and epi-
demiology questionnaires) (Table 4). An analysis at the
Melbourne and Sydney site showed that there was high
agreement between self-reported treatment data and med-
ical records (Phillips KA, Milne RL, Buys S, Friedlander ML,
Table 3
Breast cancer status and sex of probands, by ascertainment source and recruitment site (1996–2003)
Source of proband ascertainment San Franciscoa Ontario Melbourne
and Sydney
New York Philadelphia Utah Total
Population-based case probands 6126
Female, with first primary breast cancer 2038 2553 1141 5732
Female, with second breast cancer 199 91 0 290
Male 56 48 0 104
Population-based control probands 2990
Female 634 1711 645 2990
Clinic-based affected probands 1647
Female, with first primary breast cancer 0 333 177 574 241 54 1379
Female, with second breast cancer 0 27 15 152 34 20 248
Male 0 3 1 14 2 0 20
Clinic-based unaffected probands 1187
Female 0 0 179 386 489 109 1163
Male 0 0 2 8 14 0 24
Total probands 2927 4766 2160 1134 780 183 11,950
Female, with first primary breast cancer 2038 2886 1318 574 241 54 7111
Female, with second breast cancer 199 118 15 152 34 20 538
Female, without breast cancer 634 1711 824 386 489 109 4153
Male, with breast cancer 56 51 1 14 2 0 124
Male, without breast cancer 0 0 2 8 14 0 24
aIncludes probands recruited in Orange County, California, since 2001.Available online http://breast-cancer-research.com/content/6/4/R375
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Ward J, McCredie MRE, Giles GG, Hopper JL, unpub-
lished data).
Blood or mouthwash samples were collected from 4786
case probands (70% in San Francisco, 62% in Ontario,
and 71% in Melbourne and Sydney) (Table 4). An analysis
of participants at the Ontario site showed that proband
non-response at all stages (namely family history, epidemi-
ology questionnaire, and biospecimen collection) was not
associated with family history of breast or ovarian cancer
[23,24]. Lymphoblastoid cell lines were established for
1723 case probands, and tumor tissue samples were
obtained for 2675.
Relatives
A total of 22,857 relatives of case probands have been
enrolled (Table 4). The epidemiology questionnaire was
completed by 10,535 relatives. The short proxy epidemiol-
ogy questionnaire was completed for 11,155 relatives from
the Australian site. Blood or mouthwash samples were
collected for 6776 relatives. Lymphoblastoid cell lines were
established for 450 relatives, and tumor tissue was
obtained for 437 affected relatives. Collection of tumor tis-
sue is still continuing in Ontario and in Melbourne and
Sydney.
Control probands
Among women selected as control probands, 2990 com-
pleted the family history questionnaire, 2979 completed
the epidemiology questionnaire, and 1855 provided a
blood or mouthwash sample. Response to the epidemiol-
ogy questionnaire was 60% in San Francisco, 64% in
Ontario, and 68% in Melbourne and Sydney. Participation
in biospecimen collection was 56% in San Francisco and
Table 4
Epidemiology data and biospecimen collection for probands and relatives from all sites (1996–2003), by ascertainment source
Parameter Population-based families Clinic-based families Total families
Probands Relatives Probands Relatives
Affected probands and relativesa 6126 22,857 1647 4943 35,573
Affected (breast only) 6098 1856 1602 694 10,250
Affected (ovarian only) 0 158 0 81 239
Affected (breast and ovarian) 28 24 45 25 122
With epidemiology questionnaire 5250 10,535 1529 2857 20,171
With short proxy epidemiology questionnaire 0 11,155 0 1821 12,976
With blood sample 4429 6293 1524 2204 14,450
With mouthwash sample 357 483 6 31 877
With tumor tissueb 2675 437 630 151 3893
Unaffected probands and relativesa 2990 7229 1187 3321 14,727
With epidemiology questionnaire 2979 1387 1137 1747 7250
With short proxy epidemiology questionnaire 0 5842 0 1185 7027
With blood sample 1797 14 1108 1731 4650
With mouthwash sample 58 0 3 7 68
With tumor tissueb 0 1 17 382 400
All probands and relativesa 9116 30,086 2834 8264 50,300
With epidemiology questionnaire 8229 11,922 2666 4604 27,421
With short proxy epidemiology questionnaire 0 16,997 0 3006 20,003
With blood sample 6226 6307 2632 3935 19,100
With mouthwash sample 415 483 9 38 945
With tumor tissueb 2675 438 647 533 4293
aProbands with completed family history questionnaire; relatives with epidemiology data, blood or mouthwash sample, or tumor block. bTumor 
tissue for breast or ovarian cancer.Breast Cancer Research    Vol 6 No 4    John et al.
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55% in Melbourne and Sydney. Biospecimen collection is
continuing in Ontario and is expected to be completed for
45% of control probands.
The same ascertainment protocol was also used in Mel-
bourne and Sydney to recruit case and control probands
before the establishment of the Breast Cancer Family
Registry, including 467 case probands diagnosed between
1992 and 1995 with breast cancer before the age of 40
years, and 408 control probands frequency-matched to
case probands on age. Relevant data are stored at the
Informatics Center and, together with material collected
from family members, are available from the site investiga-
tors to be used in conjunction with the Breast Cancer Fam-
ily Registry resources.
Clinic-based families
A total of 2834 probands (1647 affected, 1187 unaf-
fected) have been enrolled (Table 4). Of these, 2666 com-
pleted the epidemiology questionnaire and 2641 provided
a blood or mouthwash sample (1530 affected, 1111 unaf-
fected). Lymphoblastoid cell lines were established for 738
(343 affected, 395 unaffected). Tumor blocks were
obtained for 647 probands.
A total of 8264 relatives have been enrolled, with an aver-
age of three members per family. Of these, 4604 com-
pleted the epidemiology questionnaire, and 3973 provided
a blood or mouthwash sample. The short proxy epidemiol-
ogy questionnaire was completed for 3006 relatives. Lym-
phoblastoid cell lines were established for 1014 relatives.
Tumor blocks for breast or ovarian cancer were obtained
for 533 relatives.
In addition to families presented in Table 4, more than 500
multiple-case breast cancer families have been recruited in
Australia as part of the Kathleen Cuningham Consortium
for Familial Breast Cancer (kConFab), which administered
the same epidemiology and family history questionnaires
and used the same blood collection protocol as the Breast
Cancer Family Registry. Funds for BRCA1 and BRCA2
mutation testing have been provided by the National Can-
cer Institute and these families are available to be used in
conjunction with the Breast Cancer Family Registry
resources through application to kConFab http://
www.kconfab.org.
Proband and family characteristics
The Breast Cancer Family Registry contains various sub-
groups of probands and families with specific characteris-
tics (Table 5). Among the 6779 probands with a history of
breast or ovarian cancer and a completed epidemiology
questionnaire (5250 from population-based families and
1529 from clinic-based families) there are 124 male
probands, 1526 (23%) with a diagnosis before age 40
years, 1748 (26%) from minority populations, 1040 (15%)
of Ashkenazi Jewish ancestry, 494 (7%) with a history of
two breast cancer diagnoses, 65 (1%) with a history of
both breast and ovarian cancer, 2332 (34%) with at least
one first-degree relative with breast cancer, and 61 from
participating twin pairs. The relatively high proportion
(23%) of probands diagnosed before the age of 40 years
reflects both the designs used by the population-based
sampling to increase the number of case probands with a
genetic etiology and the age at diagnosis distribution of the
multiple-case families. The relatively large proportion (26%)
of minority probands largely reflects the oversampling of
these families at the San Francisco site. Among them, 25%
are Latino, 24% are African-American, 15% are Chinese,
13% are Filipino, 4% are Japanese, and the remaining 19%
are other Asians, Pacific Islanders and others. Probands
reported 101 different countries of birth; 60% were born in
the USA or Canada, 14% in Australia or New Zealand,
12% in Europe, 9% in Asia, 4% in Latin America, and 1%
in Africa.
Among the 2834 clinic-based families enrolled so far, 204
(7%) include three or more first-degree relatives with
breast or ovarian cancer (Table 6). Among the 6126 popu-
lation-based case families this percentage is 4%. Blood or
mouthwash samples are available for 1863 sibships from
population-based case families and 701 sibships from
clinic-based families with one or more affected sisters and
one or more unaffected sisters (Table 7).
Mutational analysis of BRCA1 and BRCA2
Testing for mutations in BRCA1 has been conducted for
5656 females and 612 males, and in BRCA2 for 5497
females and 524 males (Table 8). Nearly half of those
tested (42%) were of Ashkenazi Jewish ancestry. A total of
984 mutation carriers have been detected (547 affected
with breast cancer, 437 unaffected). Among 539 female
BRCA1 mutation carriers detected, 329 (61%) had a his-
tory of breast cancer, in comparison with 207 (70%)
among 297 female BRCA2  mutation carriers detected.
There are a total of 230 population-based female mutation
carriers, making this the largest collection of population-
based carriers yet established. At some sites, BRCA1 and
BRCA2 mutation testing is continuing; the number of avail-
able mutation carriers will therefore increase.
Discussion
The Breast Cancer Family Registry has enrolled nearly
12,000 families containing individuals with a wide range of
familial risks of breast cancer. This novel research infra-
structure has many strengths, including the following: its
focus on data and biospecimen collection from both
population-based and clinic-based families, including a
large number of minority families and Ashkenazi Jewish
families from three countries; attention to quality, compara-Available online http://breast-cancer-research.com/content/6/4/R375
R385
bility, and comprehensiveness of data and biospecimen
collection; continuing molecular characterization; estab-
lishment of Epstein–Barr virus-immortalized lymphoblastoid
cell lines; and broad-based research and clinical expertise
in breast cancer represented among the six participating
sites and their international collaborators.
Table 5
Age and race/ethnicity of probandsa with a history of breast cancer from all sites (1996–2003), by ascertainment source
Parameter Population-based case probandsb 
(n = 5250)
Clinic-based affected probandsb 
(n = 1529)
Total probandsb (n = 6779)
Age at diagnosis
<30 years 132 45 177
30–39 years 1049 300 1349
40–49 years 1809 585 2394
50–59 years 1610 344 1954
≥ 60 years 650 255 905
Race/ethnicity
White 3604 1278 4882
African-American 381 45 426
Latino 330 105 435
Chinese 248 21 269
Japanese 66 0 66
Filipino 227 0 227
Other Asian or Pacific Islander 122 7 129
Mixed or other race 130 66 196
Not reported 142 7 149
Ashkenazi Jewish heritage 232 808 1040
History of second breast cancer 261 233 494
History of breast and ovarian cancer 22 43 65
Family history of breast cancer in one or 
more first-degree relatives
1677 655 2332
aProbands with completed epidemiology questionnaire. bProbands with a history of breast cancer.
Table 6
Distribution of families from all sites (1996–2003), by history of breast and ovarian cancer and ascertainment source
Number of reported 
breast and ovarian 
cancers in familya
Number of families enrolled
Population-based case families (n = 6126) Clinic-based families (n = 2834) Total families (n = 8960)
00  ( 0 % ) 1 5 2 b (5%) 152 (1%)
1 3979 (65%) 1684 (59%) 5663 (63%)
2 1873 (30%) 794 (28%) 2667 (30%)
3 240 (4%) 178 (63%) 418 (5%)
4 24 (<1%) 19 (<1%) 43 (<1%)
≥ 5 10 (<1%) 7 (<1%) 17 (<1%)
aIn proband and first-degree relatives. bBreast or ovarian cancers in second-degree relatives only.Breast Cancer Research    Vol 6 No 4    John et al.
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The Breast Cancer Family Registry includes families identi-
fied through multiple ascertainment modes, thus permitting
flexibility in the design of studies using the resources. The
infrastructure fosters collaborative interdisciplinary studies
to rapidly address a broad range of research questions
requiring large samples of data and biospecimens that are
readily available and well defined in terms of epidemiologi-
cal, clinical, and molecular characteristics. Thus, the Breast
Cancer Family Registry provides a model for studying the
genetic epidemiology of other cancers and other complex
diseases.
Extended families with multiple cases are a proven means
of discovering genes that when mutated convey a high risk
of disease [25], and are an efficient sampling design for
identifying mutation carriers for studies of genetic and envi-
ronmental risk modifiers. Sisters concordant for disease are
useful for gene discovery and for disentangling gene–gene
interactions, and sisters discordant for disease are useful
for case-control studies of putative genetic and environ-
mental risk factors. Population-based case families can be
used to characterize susceptibility genes by providing esti-
mates of penetrance and prevalence applicable to the pop-
ulation groups from which they are sampled, and, when
combined with controls and control families, can provide
multiple designs for addressing issues in the genetic epide-
miology of breast cancer [26-29]. The availability of popu-
lation-based and family-based controls within the registry,
combined with the ethnic diversity of the families, will per-
mit questions related to population stratification to be
addressed. Populations carrying founder or ancestral muta-
tions in susceptibility genes can facilitate the characteriza-
tion of specific mutations and their impact on communities,
whereas twin studies can provide new insights into the rel-
ative roles of genetic and environmental factors [30,31].
Population-based case probands and both related and
unrelated controls are important for assessing the effects
of measured genetic variants or haplotypes in candidate
genes [32], which might have a low individual risk but,
when combined, the genetic variants and haplotypes might
have a high population attributable risk, with substantial rel-
evance to public health.
The different designs and common resources available
through the Breast Cancer Family Registry can be used for
a multitude of collaborative studies; see, for example, Whit-
temore and Nelson [33] for a discussion of designs,
strengths, and weaknesses. Some of the studies and initia-
tives currently under way or in development include search-
ing for novel breast cancer susceptibility loci, testing for
association and/or linkage with variants in known candidate
genes, estimating the penetrance and detecting modifiers
of penetrance associated with variants in different genes
(including the examination of genetic and environmental
modifiers of risks associated with these variants, often
referred to as gene–gene and gene–environment interac-
tions), and developing and disseminating innovative analyt-
ical approaches and related software for the discovery and
Table 7
Distribution of sibships from all sites (1996–2003), by number of affected and unaffected sisters and ascertainment source
Number of affected 
sistersa
Number of unaffected 
sistersa
Number of sibships
Population-based case 
families
Clinic-based families Total families
1 0 4130 1649 5779
1 1 979 377 1356
1 2 382 105 487
1 ≥ 3 157 28 185
2 0 169 118 287
2 1 8 34 21 2 5
224 6 95 5
2 ≥ 31 5 2 1 7
≥ 3 0 20 14 34
≥ 3 1821 0
≥ 3 2044
≥ 3 ≥ 3 404
Total sibships 5993 2350 8343
aFull sisters with blood or mouthwash samples.Available online http://breast-cancer-research.com/content/6/4/R375
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characterization of cancer susceptibility genes. In addition,
clinical epidemiology studies are addressing prognosis and
optimal treatment for various high-risk subgroups. Social
and behavioral epidemiology studies are addressing
choices by, and behaviors of, high-risk individuals. Future
health policy and public health research might focus on
interrelationships between different legislative, health care,
and social structures and health policies related to genetic
testing and research.
Potential limitations of the Breast Cancer Family Registry
need to be considered when using its resources. There are
differences across and even within sites in designs, eligibil-
ity criteria, sampling schemes, and data collection modes
that can be used to advantage, but can be problematic if
not understood. Proper analysis and interpretation of family
studies across sites require a clear understanding of the
ascertainment procedures that have been used. As in all
family studies, biospecimens are not available from all eligi-
ble family members, and study designs and analyses need
to consider this limitation. Lastly, there is also some incom-
pleteness in the collection of questionnaire data and tumor
samples. The impact of each of these issues on specific
studies needs to be considered and, if possible, minimized.
The Breast Cancer Family Registry offers several chal-
lenges for theoretical and applied statisticians in develop-
ing optimal methods for the design and analysis of studies
using its resources. Such challenges include the following:
analyzing data from individuals who are related and from
families for whom data collection is incomplete; trying to
make inferences about either a measured genetic marker or
about the characteristics (mode of inheritance, allele fre-
quency, effects on risk) of a presumed unmeasured genetic
effect against the background of other familial effects of
unknown origin, such as polygenic inheritance or shared
Table 8
Number of currently identified BRCA1 or BRCA2 mutation carriersa from all sites (1996–2003), by sex and ascertainment source
Sex and group Status Population-based 
case families
Clinic-based families Families from 
Ashkenazi Jewish 
Project
Total families
Females
Tested for BRCA1 2 2 5 21 0 2 92 3 7 55 6 5 6
BRCA1 carriers Affectedb 110 70 149 329
Unaffected 23 100 87 210
Total 133 170 236 539
Tested for BRCA2 2255 868 2374 5497
BRCA2 carriers Affectedb 85 59 63 207
Unaffected 12 36 42 90
T o t a l 9 79 51 0 5 2 9 7
Males
Tested for BRCA1 86 137 389 612
BRCA1 carriers Affectedb 0134
Unaffected 14 44 41 99
T o t a l 1 44 54 41 0 3
Tested for BRCA2 66 73 385 524
BRCA2 carriers Affectedb 3317
Unaffected 7 13 18 38
T o t a l 1 01 61 94 5
Males and females
BRCA1 or 
BRCA2 carriers
Affected 198 133 216 547
Unaffected 56 193 188 437
Total 254 326 404 984
aCarriers of deleterious mutations. bWith a history of breast cancer.Breast Cancer Research    Vol 6 No 4    John et al.
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family environmental factors [32,34]; and how to make
appropriate adjustment for non-random or non-systematic
ascertainment of families. Researchers from the Breast
Cancer Family Registry are collaborating with other statis-
ticians to develop methods and software to facilitate appro-
priate and optimal analyses and to make these
developments available to researchers using the resource.
The development of the Breast Cancer Family Registry has
already resulted in the initiation of more than 80 hypothesis-
driven research projects among participating sites and with
the greater international research community, and has
already produced numerous publications. The Breast Can-
cer Family Registry website lists continuing collaborative
research projects http://www.cfr.epi.uci.edu/ic_registries/
breast/approved.htm and publications http://
www.cfr.epi.uci.edu/ic_registries/breast/
breast_publications.htm.
The Breast Cancer Family Registry data and biospecimens
are available to the scientific community. Researchers inter-
ested in initiating collaborative research projects using the
resources are invited to access the Breast Cancer Family
Registry website for preliminary information http://
epi.grants.cancer.gov/BCFR/index.html, and to make initial
contact with the Program Officer at the National Cancer
Institute to discuss the process of developing a collabora-
tive proposal (details are available from the corresponding
author). Interested investigators will then be referred to the
relevant investigators and Working Groups to discuss the
details of their proposal, to become acquainted with site-
specific recruitment issues, to establish collaborations, and
then to submit to the Advisory and Steering Committees a
concise proposal that includes information on the study
design and requirements for data and/or biospecimens.
Approval for the use of human subjects in accordance with
the requirements of the Office for Human Research Protec-
tions is required. For approved proposals requesting the
use of biospecimens, a Material Transfer Agreement is
required.
Conclusion
Nearly 12,000 families have been enrolled in the Breast
Cancer Family Registry, a novel research infrastructure.
Data and biospecimen resources are available for collabo-
rative, interdisciplinary, and translational studies of the
genetic epidemiology of breast cancer.
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